AEON Biopharma, Inc. Stockholders Equity

Quick Answer

AEON Biopharma, Inc. reported Stockholders Equity of -$55.03 million for fiscal year 2025.

AEON Biopharma, Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 -$55.03M -92.6%
2024 -$28.57M +81.3%
2023 -$153.04M -191.6%
2023 $167.14M +158.1%
2022 -$287.50M -1598.2%
2021 -$16.93M -79167.1%
2020 $21.4K

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 -$19.87M +38.1% -25.4%
June 30, 2025 -$15.85M +43.3% -40.0%
March 31, 2025 -$11.32M +94.3% +60.4%
December 31, 2024 -$28.57M +81.3% +11.0%
September 30, 2024 -$32.09M +73.6% -14.8%
June 30, 2024 -$27.95M -143.8% +85.9%
March 31, 2024 -$198.38M -2610.9% -29.6%
December 31, 2023 -$153.04M -25.7%
  • AEON Biopharma, Inc. showed a decrease of -92.6% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2020–2025 period, AEON Biopharma, Inc.’s stockholders equity has declined by 257091.4% (from $21.4 thousand to -$55.03 million).
  • The most recent figure is from AEON Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment